CNS5:Pleomorphic xanthoastrocytoma: Difference between revisions
| Line 219: | Line 219: | ||
|T | |T | ||
|Yes (FDA/NCCN for fusion-positive CNS tumors, not PXA-specific) | |Yes (FDA/NCCN for fusion-positive CNS tumors, not PXA-specific) | ||
| | |Targetable by TRK/ALK inhibitors (larotrectinib, entrectinib); found chiefly in pediatric BRAF-wildtype PXAs<ref>Fischer JM, Gilbert AR, Galvan EM, Singh AK, Floyd JR, Shah S. Pleomorphic xanthoastrocytoma with anaplasia and BEND5-NTRK2 fusion in a young adult with a history of cranial radiation for childhood rhabdomyosarcoma. Neurooncol Adv. 2025 Mar 8;7(1):vdaf052. doi: 10.1093/noajnl/vdaf052. PMID: 40568680; PMCID: PMC12188291.</ref> | ||
|- | |- | ||
| | | | ||